Clinical trials: Cancers of the Head and Neck
Head and Neck Cancer
Bevacizumab, Docetaxel, and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00281840
- Testing
- bevacizumab, docetaxel, conventional surgery
- Where
- 6 sites in United States
- Volunteers
- 30 people
- Sponsor
- Case Comprehensive Cancer Center
Head and Neck Cancer
Ph II Long Term/Low Dose Xeloda in Head and Neck Squamous Cell Carcinoma After Surgery, Radiation & or Chemo
RATIONALE: Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00258310
- Testing
- capecitabine, Surgery, chemotherapy and/or radiotherapy
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Head and Neck Cancer
Paclitaxel vs Paclitaxel + Cetuximab in Recurrent - Metastatic Head & Neck Carcinoma After Failure of a 1º Chemotherapy
Treatment of recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) after progression to first line EXTREME-type treatment in patients undergoing maintenance treatment with cetuximab.
- Trial name
- EXTAX (NCT03887442)
- Testing
- Paclitaxel, Cetuximab + Paclitaxel
- Volunteers
- 17 people
- Sponsor
- Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
Squamous Cell Carcinoma
Azacitidine and Cisplatin for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
To evaluate the safety and toxicity of azacitidine (5-azacitidine, Vidaza®) and cisplatin combination in patients with squamous cell carcinoma of head and neck (SCCHN).
- Trial name
- NCT00443261
- Testing
- Azacitidine, Cisplatin
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Kansas Medical Center
Basal Cell Carcinoma, Squamous Cell Carcinoma
Serum Concentration of Lidocaine After Local Injection During Mohs Micrographic Surgery
The primary objective of this study is to (1) determine whether local injection of lidocaine used during Mohs surgery will elevate serum lidocaine concentrations to a level that could cause systemic symptoms and (2) determine…
- Trial name
- NCT00793169
- Testing
- Blood Draw
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Northwestern University
Gastrointestinal Tumors, Colorectal Adenocarcinomas
Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors.
A phase 1, open-label, dose escalation and expansion study of PF-07062119 in patients with selected advanced or metastatic gastrointestinal tumors
- Conditions
- Gastrointestinal Tumors, Colorectal Adenocarcinomas, Gastric Adenocarcinomas, Esophageal Adenocarcinomas
- Trial name
- NCT04171141
- Testing
- PF-07062119, Anti-PD1, Anti-VEGF
- Where
- 19 sites in United States, Australia and 1 more
- Volunteers
- 79 people
- Sponsor
- Pfizer
Esophageal Cancer
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
RATIONALE: Biological therapies such as cetuximab may stop the growth of tumor cells by blocking the enzymes necessary for their growth.
- Trial name
- NCT00096031
- Testing
- cetuximab
- Where
- 152 sites in United States
- Volunteers
- 63 people
- Sponsor
- SWOG Cancer Research Network
Esophageal Cancer
S0356 Oxaliplatin, 5-FU, Radiation Therapy (RT), Surgery for Pts With Stage II or III Cancer of Esophagus or Gastroesophageal (GE) Junction
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin and fluorouracil, work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00086996
- Testing
- fluorouracil, oxaliplatin, conventional surgery
- Where
- 143 sites in United States
- Volunteers
- 98 people
- Sponsor
- SWOG Cancer Research Network
Squamous Cell Carcinoma of the Head and Neck, Nasopharyngeal Carcinoma
Stereotactic Body Radiotherapy for Head and Neck Tumors
This study will evaluate the local control rates as well as acute and late toxicity rates of stereotactic body radiotherapy (SBRT) for the treatment of benign and malignant head and neck tumors.
- Conditions
- Squamous Cell Carcinoma of the Head and Neck, Nasopharyngeal Carcinoma, Salivary Gland Cancer, Head and Neck Sarcoma
- Trial name
- NCT01344356
- Testing
- stereotactic body radiotherapy
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Mercy Research
Esophageal Cancer, Adenocarcinoma of the Esophagus
Efficacy and Safety of OncoGel™ Added to Chemotherapy and Radiation Before Surgery in Subjects With Esophageal Cancer
OncoGel is a new experimental drug delivery system that allows the slow continuous release of paclitaxel (an approved intravenous anticancer drug), from a gel (ReGel) over a long period of time.
- Conditions
- Esophageal Cancer, Adenocarcinoma of the Esophagus, Squamous Cell Carcinoma
- Trial name
- NCT00573131
- Testing
- OncoGel (Paclitaxel gel), cisplatin, 5-FU
- Where
- 20 sites in United States, Czechia and 2 more
- Volunteers
- 137 people
- Sponsor
- Boston Scientific Corporation
HNSCC
Single-arm Study With Bimiralisib in Patients With HNSCC Harboring NOTCH1 Loss of Function Mutations
Preclinical data and limited clinical evidence suggest that Head and Neck Squameous Cell Carcinoma tumors harboring certain mutations may respond well to PI3K/mTOR inhibition (phosphatidylinositol-3-kinase/ mammalian target of…
- Trial name
- HNSCC (NCT03740100)
- Testing
- Bimiralisib
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- M.D. Anderson Cancer Center
Carcinoma, Squamous Cell, Head and Neck Cancer
Cisplatin + Radiation in SCCHN and Correlation With Oxidative Stress Markers
Patients will receive standard of care radiation therapy to the primary tumor of the head and neck and involved nodal metastasis and draining nodal basin and either weekly cisplatin or every 3-week cisplatin in locally advanced…
- Trial name
- NCT02994069
- Testing
- Cisplatin, XRT
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Susanne Arnold
Head and Neck Cancer
Chemotherapy and Radiation Therapy (RT) With or Without Vandetanib in Treating Patients With High-Risk Stage III or Stage IV Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00720083
- Testing
- cisplatin, vandetanib, radiation therapy
- Where
- 63 sites in United States
- Volunteers
- 34 people
- Sponsor
- Radiation Therapy Oncology Group
Head and Neck Cancer, Squamous Cell Carcinoma
Pembrolizumab in Combination With CRT for LA-SCCHN
This is a single-arm, multi-site, open-label trial of pembrolizumab (MK-3475) used in combination with standard, cisplatin-based, definitive chemoradiotherapy (CRT) in patients with stage III-IVB squamous cell carcinoma of the…
- Conditions
- Head and Neck Cancer, Squamous Cell Carcinoma, Oral Cavity Cancer, Oropharynx Cancer
- Trial name
- NCT02586207
- Testing
- pembrolizumab (MK-3475), Cisplatin, Radiation
- Where
- 4 sites in United States
- Volunteers
- 59 people
- Sponsor
- Sanford Health
Esophageal Cancer
Chemotherapy, Radiation Therapy and Immunotherapy Prior to Surgery in Operable Esophageal Cancer
The purpose of this study is to see if adding two targeted drugs (bevacizumab and erlotinib) further improves the response to chemotherapy (5-FU, paclitaxel, carboplatin) and radiation therapy in patients with operable esophageal…
- Trial name
- NCT00393068
- Testing
- Erlotinib, Bevacizumab, Paclitaxel
- Where
- 9 sites in United States
- Volunteers
- 62 people
- Sponsor
- SCRI Development Innovations, LLC
Head and Neck Squamous Cell Carcinoma, Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma
Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery
This phase I/II trial studies the side effects of pembrolizumab and vorinostat in treating patients with squamous cell head and neck cancer or salivary gland cancer that has come back, has spread to other places in the body…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Recurrent Nasopharynx Carcinoma, Recurrent Salivary Gland Carcinoma
- Trial name
- NCT02538510
- Testing
- Laboratory Biomarker Analysis, Pembrolizumab, Vorinostat
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Washington
Head and Neck Cancer
Adjuvant Chemoradiation With Weekly Oxaliplatin in Resected Head and Neck Cancer
Oxaliplatin-containing regimens have been safely and successfully used in combination with concurrent radiation in treatment of solid tumors such as rectal and esophageal cancers.
- Trial name
- NCT00256308
- Testing
- Oxaliplatin, Radiation
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of California, Irvine
Squamous Cell Carcinoma of Head and Neck
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With HNSCC (Master Protocol) (Pegathor Head and Neck 204)
The study was a phase 2 multi-cohort, non-randomized, open-label, multi-center study assessing the clinical benefit of SAR444245 combined with other anticancer therapies for the treatment of participants aged 18 years and older…
- Trial name
- NCT05061420
- Testing
- Pembrolizumab, SAR444245 (Thor-707), Cetuximab
- Where
- 27 sites in United States, Argentina and 9 more
- Volunteers
- 59 people
- Sponsor
- Sanofi
Medullary Thyroid Cancer
A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer
The objective of this study is to evaluate the efficacy and safety of oral cabozantinib at a 60 mg dose compared with a 140 mg dose in subjects with progressive, metastatic MTC.
- Trial name
- EXAMINER (NCT01896479)
- Testing
- Cabozantinib (XL184) 140 mg, Cabozantinib (XL184) 60 mg
- Where
- 49 sites in Australia, Canada and 12 more
- Volunteers
- 247 people
- Sponsor
- Exelixis
Head and Neck Cancer
Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
The main purpose of this study is to compare nivolumab and ipilimumab with the extreme regimen as first line treatment in patients with recurrent or metastatic squamous cell of the head and neck cancer
- Trial name
- CheckMate 651 (NCT02741570)
- Testing
- Nivolumab, Ipilimumab, Cetuximab/Erbitux
- Where
- 133 sites in United States, Australia and 16 more
- Volunteers
- 947 people
- Sponsor
- Bristol-Myers Squibb